Cost-effectiveness of carrier screening for cystic fibrosis in Australia

UTSePress Research/Manakin Repository

Search UTSePress Research


Advanced Search

Browse

My Account

Show simple item record

dc.contributor.author Norman, Richard en_US
dc.contributor.author Van Gool, Kees en_US
dc.contributor.author Hall, Jane en_US
dc.contributor.author Delatycki, M en_US
dc.contributor.author Massie, John en_US
dc.contributor.editor en_US
dc.date.accessioned 2012-10-12T03:34:56Z
dc.date.available 2012-10-12T03:34:56Z
dc.date.issued 2012 en_US
dc.identifier 2011002222 en_US
dc.identifier.citation Norman Richard et al. 2012, 'Cost-effectiveness of carrier screening for cystic fibrosis in Australia', Elsevier, vol. 11, no. 4, pp. 281-287. en_US
dc.identifier.issn 1569-1993 en_US
dc.identifier.other C1 en_US
dc.identifier.uri http://hdl.handle.net/10453/18827
dc.description.abstract Carrier screening for cystic fibrosis is not widely available in Australia, partly due to concerns regarding its cost-effectiveness. The benefit of information from pregnancy to pregnancy has not been widely considered in existing cost-effectiveness analyses. Methods: A decision tree was constructed estimating costs and outcomes from screening, including both initial and subsequent pregnancies. Effectiveness was expressed in terms of CF births averted. Costs were collected using a health service perspective. All costs and outcomes were discounted at 5% per annum. Results: Screening reduced the annual incidence of CF births from 34 to 14/100,000 births (an aggregate number of CF births of 100.9 and 41.9 respectively). In initial pregnancies, costs in the screening arm (A$16.6. million/100,000 births) exceed those in the non-screening arm (A$13.4. million/100,000 births). The incremental cost per CF birth in initial pregnancies is therefore approximately A$150,000. However, this was reversed for subsequent pregnancies, in that the pre-collected information reduces the incidence of CF in subsequent pregnancies at low additional costs. When aggregated, the results suggest screening is likely to be cost-saving. Conclusions: The introduction of national carrier screening for cystic fibrosis should be considered, as it is likely to reduce CF incidence at an acceptable (potentially negative) cost. en_US
dc.language en_US
dc.publisher Elsevier en_US
dc.relation.hasversion Accepted manuscript version en_US
dc.relation.isbasedon http://dx.doi.org/10.1016/j.jcf.2012.02.007 en_US
dc.rights NOTICE: this is the author’s version of a work that was accepted for publication in Journal of Cystic Fibrosis. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of Cystic Fibrosis, [Volume 11, Issue 4, July 2012, Pages 281–287] DOI# http://dx.doi.org/10.1016/j.jcf.2012.02.007 en_US
dc.title Cost-effectiveness of carrier screening for cystic fibrosis in Australia en_US
dc.parent Journal of Cystic Fibrosis en_US
dc.journal.volume 11 en_US
dc.journal.number 4 en_US
dc.publocation Netherlands en_US
dc.identifier.startpage 281 en_US
dc.identifier.endpage 287 en_US
dc.cauo.name BUS.Centre for Health Economics Research and Evaluation en_US
dc.conference Verified OK en_US
dc.for 140208 en_US
dc.personcode 999404 en_US
dc.personcode 106498 en_US
dc.personcode 020116 en_US
dc.personcode 0000027255 en_US
dc.personcode 0000066353 en_US
dc.percentage 100 en_US
dc.classification.name Health Economics en_US
dc.classification.type FOR-08 en_US
dc.edition en_US
dc.custom en_US
dc.date.activity en_US
dc.location.activity en_US
dc.description.keywords Australia; Cost-effectiveness; Cystic fibrosis; Economic evaluation; Screening en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record